Alexander Afanasyev, MD
Nephrology · Louisville, KYNPI 1972505030
Payments from drug & device makers
Across 474 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Vifor Pharma, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$824
- Travere Therapeutics, Inc.$716
- Fresenius USA Marketing, Inc.$677
- plus $3K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 78 | $1,668 |
| Amgen(2 entities) | 64 | $1,255 |
| Vifor Pharma, Inc. | 55 | $1,181 |
| Otsuka America Pharmaceutical, Inc. | 35 | $824 |
| Travere Therapeutics, Inc. | 30 | $716 |
| Fresenius USA Marketing, Inc. | 40 | $677 |
| Mallinckrodt Hospital Products Inc. | 14 | $407 |
| Bayer | 31 | $406 |
| Novartis | 19 | $318 |
| OPKO Pharmaceuticals, LLC | 25 | $303 |
| Boehringer Ingelheim | 15 | $263 |
| Ardelyx, Inc. | 12 | $203 |
| Nxstage Medical, Inc. | 2 | $201 |
| Abbott | 1 | $139 |
| GSK | 9 | $131 |
| Akebia Therapeutics Inc | 7 | $115 |
| Eisai Inc. | 1 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Calliditas Therapeutics US Inc. | 4 | $70 |
| Aurinia Pharma U.S., Inc. | 5 | $69 |
| Novo Nordisk | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $41 |
| Genentech USA, Inc. | 2 | $37 |
| Invivyd Inc | 1 | $33 |
| Sanofi | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Lilly USA, LLC | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $18 |
| Leadiant Biosciences, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$9,552 in reported general payments places this provider in the 85th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Louisville
- Dawn CasterLouisville$902K
- Danny WooLouisville$427K
- Boutros El-HaddadLouisville$329K
- Abdul BuridiLouisville$187K
- Nizar AttallahLouisville$113K
- Shafic Abdul Wahab El HindiLouisville$45K
- Alfred JacobsLouisville$41K
- Lina MackelaiteLouisville$32K
- George AronoffLouisville$26K
- Jai BhimaniLouisville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.